Alzamend Neuro (ALZN) Competitors $2.18 -0.15 (-6.44%) Closing price 04:00 PM EasternExtended Trading$2.08 -0.10 (-4.59%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. QTTB, DARE, PMN, KZR, CVKD, ENLV, XCUR, LPTX, MTVA, and ALLRShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Q32 Bio (QTTB), Dare Bioscience (DARE), Promis Neurosciences (PMN), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Enlivex Therapeutics (ENLV), Exicure (XCUR), Leap Therapeutics (LPTX), MetaVia (MTVA), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Its Competitors Q32 Bio Dare Bioscience Promis Neurosciences Kezar Life Sciences Cadrenal Therapeutics Enlivex Therapeutics Exicure Leap Therapeutics MetaVia Allarity Therapeutics Alzamend Neuro (NASDAQ:ALZN) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Does the media prefer ALZN or QTTB? In the previous week, Alzamend Neuro had 8 more articles in the media than Q32 Bio. MarketBeat recorded 11 mentions for Alzamend Neuro and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.84 beat Alzamend Neuro's score of -0.44 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ALZN or QTTB? Alzamend Neuro currently has a consensus price target of $42.00, indicating a potential upside of 1,826.61%. Q32 Bio has a consensus price target of $12.17, indicating a potential upside of 240.80%. Given Alzamend Neuro's higher probable upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Q32 Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Q32 Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Which has more risk & volatility, ALZN or QTTB? Alzamend Neuro has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Is ALZN or QTTB more profitable? Alzamend Neuro's return on equity of -151.24% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A -151.24% -124.17% Q32 Bio N/A -2,709.70%-61.16% Do insiders & institutionals have more ownership in ALZN or QTTB? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by insiders. Comparatively, 40.0% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, ALZN or QTTB? Alzamend Neuro has higher earnings, but lower revenue than Q32 Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$4.51MN/AN/AQ32 Bio$1.16M37.55-$47.73M-$4.30-0.83 SummaryQ32 Bio beats Alzamend Neuro on 7 of the 12 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.85M$3.32B$6.01B$10.23BDividend YieldN/A2.29%5.66%4.69%P/E RatioN/A22.1185.3526.57Price / SalesN/A416.63582.95179.01Price / CashN/A47.1938.3262.20Price / Book0.4410.2112.726.53Net Income-$4.51M-$52.40M$3.30B$275.87M7 Day Performance-13.83%0.90%1.07%-1.40%1 Month Performance-7.23%12.36%7.61%5.16%1 Year Performance-84.86%30.17%79.71%31.51% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro2.1151 of 5 stars$2.18-6.4%$42.00+1,826.6%-83.8%$6.85MN/A0.004News CoverageInsider TradeQTTBQ32 Bio2.9706 of 5 stars$2.56+17.8%$12.17+375.8%-93.2%$31.20M$1.16M-0.5939News CoverageGap UpHigh Trading VolumeDAREDare Bioscience1.7938 of 5 stars$2.25flat$10.00+344.4%-31.6%$30.33M$10K-1.0530Positive NewsAnalyst ForecastPMNPromis Neurosciences3.4752 of 5 stars$0.53-3.8%$4.33+720.7%-50.5%$28.41MN/A-2.515Positive NewsAnalyst ForecastGap UpKZRKezar Life Sciences3.896 of 5 stars$3.88-1.4%$9.00+132.3%-49.1%$28.38MN/A-0.4060Positive NewsAnalyst ForecastHigh Trading VolumeCVKDCadrenal Therapeutics2.5639 of 5 stars$13.56+0.2%$32.00+136.0%+18.7%$27.84MN/A-1.534Analyst ForecastENLVEnlivex Therapeutics2.8412 of 5 stars$1.13-1.7%$10.00+788.9%-23.7%$27.33MN/A-1.9470Analyst ForecastXCURExicure1.6339 of 5 stars$4.26-0.2%N/A+135.7%$26.92M$500K-1.1050Analyst ForecastLPTXLeap Therapeutics2.5348 of 5 stars$0.63-18.0%$3.38+439.1%-70.9%$25.94MN/A-0.4040News CoverageAnalyst ForecastGap DownHigh Trading VolumeMTVAMetaVia2.9921 of 5 stars$1.05-2.8%$7.50+614.3%N/A$25.41MN/A0.008Analyst ForecastALLRAllarity Therapeutics2.7219 of 5 stars$1.75+5.8%$9.25+430.1%+19.7%$25.34MN/A0.0010Analyst Forecast Related Companies and Tools Related Companies Q32 Bio Competitors Dare Bioscience Competitors Promis Neurosciences Competitors Kezar Life Sciences Competitors Cadrenal Therapeutics Competitors Enlivex Therapeutics Competitors Exicure Competitors Leap Therapeutics Competitors MetaVia Competitors Allarity Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredBig Oil Firm Stakes $1 Billion in Startup That Could Kill Big OilOn September 22, the unthinkable happened... One of the world's biggest oil producers poured $1 billion int...Stansberry Research | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
